A custom NGS panel covering 27 IARC carcinogenic HPV genotypes enabled detection of ccfHPV DNA across treatment strata and ...

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

Researchers found that recurrence occurred in 35 and 63% of women in the partner-treatment and control groups, respectively. HealthDay News — Treating male partners in addition to women with bacterial ...

LOUISVILLE, Ky. -- Minimally invasive ablative therapy for early kidney cancer had an increased risk of local and metastatic recurrence, which is associated with increased mortality, Swedish ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Breast cancer is a pervasive health concern that affects women globally, but its impact varies significantly across different demographics. Among these, Black women face unique challenges that ...

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

In a study of 206 surgical procedures for hidradenitis suppurativa (HS), the overall recurrence rate was 18.5%. Two distinct recurrence patterns were identified — tunnel recurrence occurred in 8.3% of ...

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, ...